ERBB2 and breast cancer: The HER2-overexpressing subtype, comprising approximately 15% of all invasive BC cases, exhibits a heightened expression of HER2/HER2 signaling-associated genes, leading to a more aggressive clinical course, albeit with a favorable response to anti-HER2-targeted therapy.